Biomarin Pharmaceutical Inc. (BMRN) intrinsic value & 10-year financials
Biomarin Pharmaceutical Inc. (BMRN) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 12.5% a year to $3.2B, with an average return on invested capital of -0.8%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $54.68
- Market cap
- $10.8B
- Revenue (FY2025)
- $3.2B
- Revenue growth (10-yr CAGR)
- 12.5%
- ROIC (10-yr avg)
- -0.8%
- Free cash flow (FY2025)
- $725.0M
BMRN 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $3.2B | $348.9M | $1.80 | $725.0M | 12.7% | 5.8% |
| FY2024 | $2.9B | $426.9M | $2.21 | $487.4M | 17.0% | 8.5% |
| FY2023 | $2.4B | $167.6M | $0.87 | $62.6M | 6.5% | 3.5% |
| FY2022 | $2.1B | $141.6M | $0.75 | $54.9M | 7.1% | 3.7% |
| FY2021 | $1.8B | -$64.1M | -$0.35 | $209.0M | -4.5% | -1.9% |
| FY2020 | $1.9B | $859.1M | $4.53 | -$28.9M | -2.0% | -0.6% |
| FY2019 | $1.7B | -$23.8M | -$0.13 | -$96.8M | -5.9% | -1.8% |
| FY2018 | $1.5B | -$77.2M | -$0.44 | -$124.4M | -8.3% | -2.3% |
| FY2017 | $1.3B | -$117.0M | -$0.67 | -$208.0M | -1.1% | -0.5% |
| FY2016 | $1.1B | -$630.2M | -$3.81 | -$376.2M | -71.9% | -22.0% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
BIOMARIN PHARMACEUTICAL INC is a consistent compounder, expanding top-line revenue at 12.5% annually over the past decade.
BIOMARIN PHARMACEUTICAL INC has historically struggled to out-earn its cost of capital, averaging just 2.4% ROIC.
BIOMARIN PHARMACEUTICAL INC has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, BIOMARIN PHARMACEUTICAL INC is modeled at -16.9% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-39.17 per share.